Monoclonal Antibodies to FCRL5 (CD307e/IRTA2/FcRH5) as Therapeutics and Diagnostics for B-cell Cancers
Posted Sep 28 2011 8:00pm
Description of Invention: The Fc receptor-like (FCRL) genes (also known as CD307, IRTA, FcRH, IFGP or SPAP) encode cell membrane proteins that are believed to play roles in immunity and B cell differentiation. Some FCRL genes have been implicated in B cell lymphomas and multiple myelomas. Data suggest that the FCRL1-5 proteins are expressed differently on malignant B cells as well as subpopulations of normal B cells. Due to this differential expression, FCRL proteins represent potential targets for the treatment of cancers of a B cell origin.
This technology relates to the development of novel monoclonal antibodies for a specific member of the FCRL protein family: FCRL5. FCRL5 is normally induced on mature B cells upon activation, but its expression is deregulated in multiple myeloma and Burkitt's lymphoma. Due to the correlation of FCRL5 overexpression and B cell malignancies, antibodies to FCRL5 may have value as a therapeutic or diagnostic tool. Specifically, the antibodies can be used as therapeutic agents by themselves or they can be attached to a cytotoxic agent such as Pseudomonas exotoxin A. Alternatively, the antibodies can be used to detect the deregulation of FCRL5 as a means of diagnosing B cell malignancies.
Detection or diagnosis of B cell cancers using monoclonal antibodies to FCRL5
Treatment of B cell cancers using monoclonal antibodies to FCRL5 for inducing antibody-dependent cell death
Treatment of B cell cancers using monoclonal antibodies to FCRL5 for targeting cytotoxic agents specifically to cancer cells (e.g., immunotoxins)
No cross-reactivity with other FCRL proteins demonstrates strong selectivity as both a therapeutic and diagnostic agent
Targeted therapeutics such as monoclonal antibodies and immunotoxins decrease non-specific killing of healthy, essential cells, resulting in fewer side-effects and healthier patients
For Licensing Information Please Contact: David Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4632 Fax: 301-402-0220